dromlakhani Manage perioperative care for patients undergoing PA intervention
STEP 1 — Gather Information
Collect laterality status (unilateral vs bilateral PA) via AVS or imaging, assess for resistant hypertension, serum potassium, baseline eGFR, and perform dexamethasone suppression test if adrenal tumor on CT to evaluate cortisol co-secretion.
STEP 2 — Rule In / Rule Out
Rule in unilateral PA (indication for adrenalectomy); if bilateral PA, defer to medical management and end perioperative pathway.
STEP 3 — Classify or Stratify
Stratify preoperative risk: high risk if resistant hypertension, hypokalemia (K+ <3.5 mmol/L), cardiovascular complications, or cortisol co‑secretion positive; low risk if none.
STEP 4 — Decide
For high‑risk patients, initiate MRAs (e.g., spironolactone 25–50 mg/day) to control BP and hypokalemia pre‑op; plan glucocorticoid replacement (hydrocortisone 20 mg/day tapered) if cortisol co‑secretion confirmed; post‑op monitor serum K+ and creatinine/eGFR q6h for 24h, treat hyperkalemia (K+ >6.0 mmol/L) with calcium gluconate/insulin/beta‑agonist and adjust MRAs accordingly.
Clinical Guardrails / Mimics / Pitfalls
Do not delay adrenalectomy for uncontrolled hypertension without attempting MRA optimization; avoid potassium supplementation in patients on eplerenone or esaxerenone; do not ignore postoperative hyperkalemia or rising creatinine; avoid excessive glucocorticoid dosing without evidence of cortisol co‑secretion.
Concrete Clinical Example
A 34‑year‑old man with unilateral PA (AVS LI >4), K+ 3.1 mmol/L, resistant hypertension, and adrenal tumor on CT with positive dexamethasone suppression test (cortisol >1.8 µg/dL). Pre‑op spironolactone 50 mg/day normalized K+ and BP. Underwent laparoscopic adrenalectomy. Received hydrocortisone 20 mg TAPERED over 3 days. Post‑op K+ remained 4.2–4.8 mmol/L, eGFR stable; no hyperkalemia.
Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2022